@Raffout @Fid Im fairly certain Renovo would not fall under IV...

@Raffout @Fid

Im fairly certain Renovo would not fall under IV or IT. Introducing a new drug delivery system into the trials would not be acceptable to the FDA.

This will need its own FDA Trial approval with its own specific design . Which would be designed using the pre-clinical data.

And in all likelihood would include Pancreatic Cancer and perhaps other hard to access tumors.

The encouraging factor here is that Renovo keeps referring to CF33 in their company presentations. So it hasn’t failed and mouse studies. It may in fact be showing positive progress!